Demonstrates an association between ustekinumab levels and treatment outcomes in Crohn's disease, suggesting future decision-making processes.
This study confirms the association between ustekinumab concentrations at week 8 and treatment effectiveness in Crohn's disease. A concentration >13.29 μg/mL at week 8 was identified as a predictive marker of biochemical remission at week 24, which could serve as a basis for future therapeutic decision-making algorithms.
No takes yet. Share an insight, caveat, or question.
García et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: